Stagwell (STGW) Soars After Q3 Beat and Palantir AI Partnership; 2025 Outlook Calls for ~8% Net Revenue Growth (Nov. 6, 2025)

Stagwell (STGW) Soars After Q3 Beat and Palantir AI Partnership; 2025 Outlook Calls for ~8% Net Revenue Growth (Nov. 6, 2025)

  • Q3 headline results: Revenue $743M (+4% YoY); GAAP EPS $0.09; Adjusted EPS $0.24; Adjusted EBITDA $115M. [1]
  • 2025 guidance (reaffirmed): Net revenue growth ~8%, Adjusted EBITDA $410M–$460M, Adjusted EPS $0.75–$0.88, FCF conversion >45%. [2]
  • New AI alliance:Stagwell x Palantir to build an AI-driven marketing and data platform; early MVP already in client use via Stagwell’s media arm, Assembly. [3]
  • Stock reaction: STGW ripped higher after the open; shares were ~39% higher near $6.70 by mid‑morning U.S. Eastern time. [4]

What’s new today

Earnings: Stagwell Inc. (NASDAQ: STGW) reported third‑quarter revenue of $743 million, GAAP EPS of $0.09, and adjusted EPS of $0.24. Management highlighted double‑digit “ex‑advocacy” momentum, with net revenue ex‑advocacy up 10% to $578 million, and adjusted EBITDA of $115 million (19% margin on net revenue). The company also pointed to $122 million in net new business for the quarter and a $100 million year‑to‑date improvement in operating cash flow versus last year. [5]

Independent wire coverage from the Associated Press echoed the headline figures and noted the full‑year adjusted EPS range of $0.75–$0.88. [6]

Street scorecard: Zacks said Stagwell topped consensus on both EPS ($0.24 vs. $0.23) and revenue ($743M vs. $734M), framing the quarter as a modest beat. [7]

AI partnership: Before the bell, Stagwell and Palantir (PLTR) unveiled a partnership to create an AI‑driven, privacy‑aware marketing platform that stitches together Palantir Foundry, Code and Theory’s orchestration software, and The Marketing Cloud data. Stagwell said early client adoption is underway via Assembly, with a broader rollout to follow; CEO Mark Penn said the opportunity could be “potentially hundreds of millions of dollars” in revenue over time. [8]

As of 14:43 UTC (9:43 a.m. ET), STGW traded around $6.31 after opening sharply higher; the intraday range had already stretched from roughly $5.00 to $8.86 in early trading.
Real‑time market dashboards also showed shares up ~39% near $6.70 by mid‑morning, reflecting both the earnings print and the Palantir deal headlines. [9]


Guidance and operating color

Stagwell reiterated 2025 guidance for ~8% net revenue growth, Adjusted EBITDA of $410M–$460M, Adjusted EPS of $0.75–$0.88, and free‑cash‑flow conversion above 45%. Management emphasized cost discipline (labor efficiency), non‑advocacy growth, and an improving cash‑flow profile as support for the outlook into year‑end. [10]


Why it matters

  • AI arms race in advertising: The Palantir tie‑up gives Stagwell a differentiated, data‑to‑activation stack at a time when holding companies are racing to productize AI. Early MVP usage via Assembly suggests near‑term commercialization paths rather than a purely aspirational roadmap. [11]
  • Execution against targets: With Q3 adjusted EPS and revenue ahead of consensus and ex‑advocacy growth running double‑digits, Stagwell is signaling continued progress on its “technology‑led challenger” thesis while pacing to its 2025 targets. [12]

By the numbers (Q3 2025)

  • Revenue:$743M (+4% YoY)
  • Net revenue ex‑advocacy:$578M (+10% YoY)
  • Adjusted EBITDA:$115M (19% margin on net revenue)
  • GAAP EPS / Adjusted EPS:$0.09 / $0.24
  • Net new business:$122M (LTM $472M)
  • Operating cash flow (YTD):$31M (up $100M YoY)
  • 2025 guide:~8% net revenue growth; Adj. EBITDA $410M–$460M; Adj. EPS $0.75–$0.88; FCF conversion >45%. [13]

What’s next

Stagwell’s Q3 2025 earnings webcast was scheduled for 8:30 a.m. ET today, with a replay to be posted on the company’s investor site. Look for management commentary on early customer use‑cases for the Palantir platform and the puts and takes in advocacy vs. non‑advocacy as the company heads into Q4. [14]


Sources & further reading

  • Stagwell Q3 2025 press release (full financials, guidance, webcast details). [15]
  • AP earnings snapshot (headline results, guidance range). [16]
  • Zacks/Finviz (consensus context: EPS and revenue beat). [17]
  • Stagwell–Palantir partnership announcement (platform architecture, deployment plan, management quotes). [18]
  • Live market snapshot (shares +~39% mid‑morning). [19]
스태그웰 Inc. (STGW) 투자 분석: 디지털 전환과 AI 기반 마케팅 플랫폼

References

1. www.prnewswire.com, 2. www.prnewswire.com, 3. www.prnewswire.com, 4. www.marketscreener.com, 5. www.prnewswire.com, 6. www.timesunion.com, 7. finviz.com, 8. www.prnewswire.com, 9. www.marketscreener.com, 10. www.prnewswire.com, 11. www.prnewswire.com, 12. finviz.com, 13. www.prnewswire.com, 14. www.prnewswire.com, 15. www.prnewswire.com, 16. www.timesunion.com, 17. finviz.com, 18. www.prnewswire.com, 19. www.marketscreener.com

Stock Market Today

  • Regenxbio (RGNX) Q3: Loss Narrower, Revenue Beat; Zacks Rank Upgraded to Buy
    November 6, 2025, 12:46 PM EST. Regenxbio (RGNX) posted a Q3 loss of $1.20 per share, beating the consensus loss of $1.38 and delivering a +13.04% earnings surprise. Revenue was $29.73 million, surpassing the consensus by 23.73% versus $24.2 million a year ago. The stock has risen roughly 50.2% year-to-date, outpacing the S&P 500's 15.6%. The company carries Zacks Rank #2 (Buy) amid favorable earnings estimate revisions. Looking ahead, the current quarter is seen at $0.27 EPS on $108.94 million in revenue, with the full-year view at -$2.43 on $228 million in revenue. The outlook for the Medical - Biomedical & Genetics group remains a factor for Regenxbio.
  • Advanced Drainage Systems (WMS) Beats Q2 EPS and Revenue Estimates
    November 6, 2025, 12:44 PM EST. Advanced Drainage Systems (WMS) posted Q2 earnings of $1.97 per share, beating the Zacks Consensus Estimate of $1.70. Revenue came in at $850.38 million, topping the estimate by 5.65%. Year-ago EPS was $1.70, and the company has topped consensus in three of the last four quarters on revenue guidance. The stock is up about 16.6% year-to-date, modestly ahead of the S&P 500. The firm holds a Zacks Rank #3 (Hold), with near-term outlook tied to management commentary and earnings revisions for the coming quarter and fiscal year-current projections call for $1.16 EPS on $690.32 million revenue next quarter and $5.87 on $2.96 billion for the year.
  • QuantumScape Extends Cash Runway to 2029, Refocusing on Licensing Growth
    November 6, 2025, 12:42 PM EST. QuantumScape extended its liquidity runway to 2029, reinforcing its capital-light licensing strategy with partners like PowerCo, Murata and Corning. The company finished Q3 with about $1 billion in liquidity, aided by a $263.5 million at-the-market raise and tighter capex, guiding full-year capex to $30-$40 million and Adjusted EBITDA of $245-$260 million. The longer runway eases near-term fundraising pressure and supports development and industrialization, including scaling the Cobra separator process and advancing B1 cells. In Q3, QuantumScape invoiced $12.8 million in billings (not revenue), signaling early monetization and growing partner engagement. Risks include scaling performance, converting billings to recurring revenue, and securing future licensing deals. QS has outperformed peers and jumped ~242% YTD, though execution remains key.
  • Gogo (GOGO) Beats Q3 Earnings and Revenue Estimates Amid Mixed Outlook
    November 6, 2025, 12:40 PM EST. Gogo (GOGO) reported Q3 earnings of $0.10 per share, topping the Zacks Consensus of $0.07 and marking a +42.86% surprise from the quarter. Revenue reached $223.59 million, slightly above the consensus by 0.2%, up from $100.53 million a year earlier. The company has surpassed EPS estimates in all four of the last four quarters. Management commentary on the upcoming earnings call will be crucial to gauge the sustainability of the move, as the stock has gained about 8.3% year-to-date versus the S&P 500's 15.6% gain. The current Zacks Rank remains #3 Hold, with near-term estimates for next quarter at $0.05 on $226.45 million in revenue and the current fiscal year at $0.30 on $905.94 million in revenue. Industry expectations for Wireless National remain a headwind.
  • C4 Therapeutics Q3 Loss Narrower, Revenue Beats Estimates; Zacks Rank Up (Buy)
    November 6, 2025, 12:37 PM EST. C4 Therapeutics (CCCC) posted Q3 loss of $0.44 per share, better than the Zacks consensus of a $0.47 loss and up from $0.35 a year ago (adjusted for non-recurring items), delivering an earnings surprise of +6.38%. Revenue came in at $11.23 million, topping the consensus by 72.77% and down from $15.36 million a year earlier. The stock has shed about 34.2% this year, underperforming the S&P 500's 15.6% gain. On the outlook, near-term estimates were favorable going into the print, and C4 remains rated Zacks Rank #2 (Buy), with current consensus for the next quarter at -$0.29 on $9.5 million in revenues and -$1.46 on $29.7 million for the full year. Investors will await management commentary on the earnings call.
Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025
Previous Story

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

BIYA Soars Over 100% on November 6, 2025: Baiya International’s Volatile Rally, Massive Volume, and What to Watch Ahead of 25‑for‑1 Share Consolidation Vote
Next Story

BIYA Soars Over 100% on November 6, 2025: Baiya International’s Volatile Rally, Massive Volume, and What to Watch Ahead of 25‑for‑1 Share Consolidation Vote

Go toTop